ClinicalTrials.Veeva

Menu

Collection of Samples and Clinical Data From Patients With Amyloid Diseases

Boston Medical Center (BMC) logo

Boston Medical Center (BMC)

Status

Enrolling

Conditions

Multiple Myeloma

Treatments

Genetic: clonality analysis
Genetic: protein analysis
Other: biologic sample preservation procedure
Other: laboratory biomarker analysis
Genetic: polymerase chain reaction
Procedure: fluorescence spectroscopy
Procedure: quality-of-life assessment

Study type

Observational

Funder types

Other

Identifiers

NCT00898235
CDR0000632869 (Other Grant/Funding Number)
H-22838

Details and patient eligibility

About

RATIONALE: Collecting and storing samples of blood, urine, tissue and data from patients with amyloid diseases to test in the laboratory may help the study of this disease in the future.

PURPOSE: This research study is collecting samples from patients with amyloid diseases

Full description

OBJECTIVES:

  • To establish and maintain a database of clinical material (i.e., blood, urine, and tissue) and information on patients with amyloid diseases.

OUTLINE: Blood, urine, tissue, and bone marrow samples are collected during standard laboratory evaluations to maintain a repository of biospecimens in the Gerry Amyloid Research Laboratory, to permit the correlation of clinical results with measured biological events, and for future research studies. Bone marrow RNA samples are examined for immunoglobulin light-chain gene sequences and amino acids by polymerase chain reaction and positional cloning. Blood serum and urine samples are evaluated for amyloid protein stability by high-resolution calorimetry, isothermal-titration calorimetry, and far- and near-UV circular dichroism and fluorescence spectroscopy. Urine samples are also examined for post-translational modifications (e.g., glycosylation, sulfation, and cross-linking) to identify common features unique to amyloid proteins. Tissue samples are analyzed for biochemical and biophysical properties and for post-translational modifications in light chains.

Quality of life is assessed by the 36-Item Short Form Survey (SF-36).

Enrollment

10,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

DISEASE CHARACTERISTICS:

  • Diagnosis or suspicion of amyloidosis

PATIENT CHARACTERISTICS:

  • Referred to the Amyloid Treatment and Research Center at Boston University Medical Center

PRIOR CONCURRENT THERAPY:

  • Not specified

Exclusion criteria

None

Trial contacts and locations

1

Loading...

Central trial contact

Annie Jose, BS; Vaishali Sanchorawala, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems